tbuckley/cabot-search huggingface dataset:
Abstract 3259: Intra-Aortic Balloon Pump Insertion Prior to LVAD Implantation Improves Short-term Survival in High-Risk LVAD Recipients
Authors: Tariq M Naseem, George M Comas, Abeel A Mangi, Timothy P Martens, Faisal H Cheema, Hiba Arif, Darren A Bialo, Imran Khalid, Michael Argenziano, Yoshifumi Naka
Journal: Circulation (2007)

INTRODUCTION: Intra-aortic balloon pump (IABP) insertion can augment cardiac function in the setting of acutely decompensated heart failure. The aim of this study was to determine if IABP insertion prior to left ventricular assist device (LVAD) implantation improves outcomes in LVAD recipients. HYPOTHESIS: We assessed the hypothesis that pre-operative IABP insertion for hemodynamic stability and improved organ perfusion would lead to better outcomes post-LVAD implant METHODS: We have previously described a preoperative LVAD risk score (LRS), which is based on preoperative characteristics associated with inferior outcomes after LVAD insertion (e.g. previous cardiac surgery, ventilator dependence, elevated central venous pressure, elevated prothrombin time). We retrospectively reviewed the records of 245 patients undergoing LVAD implantation (Heartmate I, Heartmate II &amp; DeBakey) at our center between 1996 and 2006, including preoperative LRS and 30-day survival. Patients were categorized as those who received an IABP prior to LVAD implant for hemodynamic stability and those who did not. Data were analyzed by Chi-square and Mann-Whitney U tests. RESULTS: Of 245 patients having LVAD implants during the study period, 174 (71%) had a LRS of 1–5 (low-risk group), while 71 (29%) had a LRS of 6 –10 (high-risk group). A total of 95 patients received an IABP prior to LVAD insertion during this period: 54 (31%) of the low-risk patients and 41 (58%) of the high-risk patients. In the high-risk cohort, patients receiving pre-operative IABP (n = 41) had superior 30-day survival compared with patients who did not receive an IABP (n = 30) (78% vs. 57%, p &lt; 0.05). Conversely, in the low-risk group, IABP insertion was associated with a trend toward lower 30-day survival (78% vs. 92%, p &lt; 0.1). In the low-risk group, the rate of successful bridging to transplantation was higher in patients who did not receive pre-operative IABP support (86% vs. 69%, p &lt; 0.01). CONCLUSION: LVAD candidates with a high LVAD risk score, a preoperative surrogate of increased perioperative risk, have improved 30-day survival if stabilized with an IABP prior to LVAD implantation.
Guiding the guidelines
Authors: None The Lancet
Journal: The Lancet (2011)

On March 23, the US Institute of Medicine (IOM) released two complementary sets of standards to improve the quality of systematic reviews and clinical practice guidelines. As the IOM points out, clinicians can be overwhelmed by the quantity of reported clinical evidence, and often need to rely on aggregated evidence to guide decision making (ie, systematic reviews and guidelines). But how well such reviews and guidelines can or should be done was the question posed to the IOM. Their answer includes 21 standards for systematic reviews and eight for guidelines.
GLYCOGEN IN MUSCLE
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de E. Assenat et al., pp. 309
Journal: Endoscopy (2007)

See also: The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower-third rectal adenocarcinomaEndoscopy 2007; 39(04): 309-313DOI: 10.1055/s-2007-966211
Medicine
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Familial dysautonomia
Authors: J. Bartels
Journal: JAMA (1970)

Familial dysautonomia is a rare disorder seen almost exclusively in Jewish children. On the basis of past experience, there has been great reluctance to subject these patients to general anesthesia. The principal autonomic disorder that makes anesthesia dangerous appears to be a lack of endogenous catecholamine when the stress of anesthesia or surgery or both calls for this substance. In the case described here, carefully titrated exogenous epinephrine was a decisive factor in the successful management of anesthesia for major thoracic surgery.
Septic bursitis
Authors: G. R. Thompson
Journal: JAMA (1978)

In 12 cases of septic bursitis seen during 11 years, 11 patients were men and one patient was a woman, with a mean age of 51.3 years. The olecranon bursa was involved in nine cases.<i>Staphylococcus aureus</i>was grown from nine of ten culture-positive fluids. Bursal fluid WBC counts ranged from 1,550/cu mm to 165,000/cu mm, associated with low glucose levels in two cases, but not in three. Treatment with antibiotics and needle aspiration or surgical drainage was successful. (<i>JAMA</i>240:2280-2281, 1978)
Abstract 747: Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients
Authors: Suk Woo Nam, Sang Yean Kim, Hyung Seok Kim, Hee Doo Yang, Min Jeong Na
Journal: Cancer Research (2019)

Abstract Pericardial effusion (PE) can develop in patients with virtually any condition that affects the pericardium, including acute pericarditis and a variety of systemic disorders. PE is also common in cancer patients, and that may develop by several different mechanisms by direct or metastatic spread of the primary process or as a complication of antineoplastic therapies. Thus, definite differentiation of malignant PE and rapid diagnosis are of particular therapeutic and prognostic importance. We aim to determine etiology-based characteristic molecular changes of PE in pericardial disorder patients, and to identify novel molecular signature for early detection of cancer patients with pericardial disorder. We obtained pericardial fluids from the pericardial disorders including cancer patients. Whole genomic transcriptome scan resulted in 1,639 outlier genes as cancer-specific PE molecular signature. Further analysis showed that a cancer-specific molecular signature exists and discerns cancer patients with non-cancer patients, and that also suggested 191 gene elements as stringent classifier between cancer vs non-cancer (Welch’s t test, p &amp;lt; 0.05 and Ven diagrammatic analysis). Gene set enrichment analysis (GSEA) with additional computational analysis of 1,639 cancer-specific PE molecular signature identified CD24, SDC1, and ST14 as strong molecular markers for identifying cancer in PE patients. In conclusion, whole transcriptomic analysis of pericardial fluids of pericardial disorder patients suggest that etiology-specific molecular signatures can discriminate different patterns of PE, and that they provide useful information for mechanistic studies that may lead to a better understanding of the molecular basis of PE pathology. Keywords: pericardial fluid, differential gene expression, diagnostic markers, CD24, SDC1, ST14 Citation Format: Suk Woo Nam, Sang Yean Kim, Hyung Seok Kim, Hee Doo Yang, Min Jeong Na. Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 747.
Risk factors for AIDS among Haitians residing in the United States. Evidence of heterosexual transmission. The Collaborative Study Group of AIDS in Haitian-Americans
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Bronchopulmonary Lavage on Lung Retention and Clearance of Particulate Material in Hamsters
Authors: Michele Ellender, Alan Hodgson, Kathyrn L. Wood, John C. Moody
Journal: Environmental Health Perspectives (1992)

Hamsters were exposed to an aerosol of fused aluminosilicate particles (FAP) labeled with 57Co. Three groups of animals were given bronchopulmonary lavage, beginning at either 1 week, 1 month, or 6 months after exposure. Each treated group was lavaged eight times over a period of 25 days. Each lavage involved 10 saline washes of the lungs. For each group, about 60-70% of the body content of 57Co at the start of lavage treatment was removed; nearly half of this was recovered in the first two lavages. A positive correlation was demonstrated between the macrophage content and 57Co activity of the washings. The subsequent fractional clearance rate of 57Co from lavaged animals was not significantly different from that in a group of untreated control animals.
Resident Stress
Authors: Louis M. Soletsky
Journal: Annals of Internal Medicine (2003)

Letters7 January 2003Resident StressLouis M. Soletsky, MDLouis M. Soletsky, MDGreat Neck, NY 11021 (Soletsky)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-1-200301070-00027-w2 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In his editorial, Dr. Cohen says that for residents in the old days, the pace of life was a lot slower, and the stresses were a lot more manageable (1). In my old days, more than 50 years ago, there were plenty of stresses. I think time may have softened Dr. Cohen's recollections. We did have a lot of joy in our lives, though: We rounded daily with eminent senior physicians and shared their interactions with patients. The hidden curriculum did not come just from our contemporaries.A few years ago, when I enjoyed the luxury of ...Reference1. Cohen JJ. Heeding the plea to deal with resident stress [Editorial]. Ann Intern Med. 2002;136:394-5. [PMID: 11874313] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Great Neck, NY 11021 (Soletsky) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHeeding the Plea To Deal with Resident Stress Jordan J. Cohen Metrics 7 January 2003Volume 138, Issue 1Page: W13KeywordsResidency ePublished: 7 January 2003 Issue Published: 7 January 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Estimating survival time in older adults receiving chemotherapy for advanced cancer.
Authors: Erin Moth, Prunella Blinman, Natalie Stefanic, Vasi Naganathan, Andrew James Martin, Peter S. Grimison, Martin R. Stockler, Philip James Beale, Belinda Emma Kiely
Journal: Journal of Clinical Oncology (2019)

e23017 Background: Best-case, worst-case, and typical scenarios for survival time, based on an oncologist’s estimate of expected survival time (EST), have proven accurate in a range of advanced cancers. We sought the accuracy and prognostic significance of such estimates, and of a simple, pragmatic rating of frailty, in older adults starting chemotherapy. Methods: Participants (pts) were aged 65 or older and starting a new line of chemotherapy for advanced cancer. For each pt at baseline, their treating oncologist recorded an individualised estimate of EST (median survival in a group of similar patients), ECOG performance status (PS), and rating of frailty with the single-item, Clinical Frailty Scale from the Canadian Study of Health and Aging. We hypothesised that estimates of EST would be unbiased (approximately 50% of pts would live longer than their EST); imprecise ( &lt; 33% would live for 0.67 to 1.33 times their EST); and, that simple multiples of the EST would provide accurate individualised scenarios for survival time, i.e. approximately 10% of pts would die within ¼ of their EST, 10% would live longer than 3 times their EST, and 50% would live from half to double their EST. We identified independent predictors of observed survival time (OST) with multivariable Cox regression. Results: Baseline characteristics of the 102 pts were: median age 74 (range 65-86), 1 st line chemotherapy in 67%, colorectal cancer in 33%, PS 0 or 1 in 80%, and frailty rating of vulnerable to frail in 35%. The median EST was 15 months (range 4-60), median follow-up time was 19 months (range 0-27), and median OST was 15 months (range 0.5-27+). As hypothesized, 54% of pts lived longer than their EST, 30% lived within 0.67 to 1.33 times their EST, 56% lived half to double their EST, and 9% lived ≤1/4 of their EST. Follow-up was too short to observe those who will live ≥3 times their EST. Independent predictors of OST were frailty (HR 2.8, 95%CI 1.6-4.9, p = 0.0004) and EST (HR 0.96, 95%CI 0.93-0.99, p = 0.03). Conclusions: Oncologists’ estimates of EST were unbiased, imprecise, and accurate for formulating scenarios for survival time. A simple, pragmatic rating of frailty by the treating oncologist was a strong predictor of OST even after accounting for their estimate of EST.
Homogeneous distribution of phosphofructokinase in the rat liver acinus: A quantitative histochemical study
Authors: W Frederiks
Journal: Hepatology (1991)

A quantitative histochemical method was developed for the demonstration in rat liver of the activity of phosphofructokinase, one of the enzymes assumed to be rate-limiting for glycolysis. The procedure was based on the reduction of a tetrazolium salt as final electron acceptor and a multistep reaction using the exogenous or endogenous auxiliary enzymes aldolase, triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase. The highest activity was found in unfixed cryostat sections of rat liver when the incubation medium contained 17% (wt/vol) polyvinyl alcohol, 100 mmol/L Tris-maleate buffer (pH 8.4), 20 mmol/L fructose-6-phosphate, 2 mmol/L ATP, 2 mmol/L MgCl2, 5.9 mmol/L NAD+, 0.47 mmol/L 1-methoxyphenazine methosulfate, 5 mmol/L sodium azide and 5 mmol/L Nitro BT. The addition of auxiliary enzymes was not necessary to demonstrate maximum activity in rat liver. The specificity of the reaction was proven by the absence of any specific (test minus control) reaction when the incubation was performed in the presence of 25 mmol/L phosphoenolpyruvate, a competitive inhibitor of phosphofructokinase. Cytophotometric analysis revealed that linear relationships exist between the amount of specific reaction product formed and incubation time and the section thickness. The Km values for fructose-6-phosphate and the Vmax values were not significantly different in periportal and pericentral areas of livers from either normally fed or 24-hr-fasted rats. The homogeneous distribution of phosphofructokinase activity in the liver acinus is in line with biochemical findings using hepatocytes isolated from the two different areas showing that these cells contained similar amounts of enzyme activity. It indicates that either phosphofructokinase is not a rate-limiting enzyme of glycolysis or the capacity for glycolysis is not different in periportal and pericentral areas of the rat liver acinus. (HEPATOLOGY 1991;14:634–639.)
ANCAs away
Authors: I G McFARLANE
Journal: Gut (1999)

<h3>Introduction</h3> Several case-control studies have suggested inverse associations between whole grain intake and colorectal cancer risk, but few cohort studies have been published on the subject. As part of the Continuous Update Project of the World Cancer Research Fund we conducted a systematic review and meta-analysis of whole grain intake and colorectal cancer risk. <h3>Methods</h3> We searched the Pubmed database for prospective cohort and nested case-control studies of whole grain intake and risk of incident colorectal cancer, up to December 2010. Summary RRs were calculated using a random effects model. <h3>Results</h3> Seven cohort studies reported results for total whole grain intake and colorectal cancer risk. The summary RR for high vs low intake of whole grain was 0.79 (95% CI 0.72 to 0.86), with no significant heterogeneity, I<sup>2</sup>=0%. The summary RR for a 3 servings per day increment was 0.81 (95% CI 0.75 to 0.88), with little heterogeneity, I<sup>2</sup>=15%. A similar reduction in risk was also found for colon cancer (summary RR=0.81, 95% CI 0.70 to 0.95, I<sup>2</sup>=0%), but the result for rectal cancer was not statistically significant and there was substantial heterogeneity (summary RR=0.75, 95% CI 0.53 to 1.08, I<sup>2</sup>=87%). <h3>Conclusion</h3> Our results support the hypothesis that whole grain consumption protects against colorectal cancer.
Modern Medicine.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression and activity of metalloprotease-2 in tumoral and non-tumoral areas of livers with metastasis Unit� de Recherches H�patologiques, INSERM U-49, *Laboratoire d'Anatomie Pathologique B, +Clinique Chirurgicale B, Facult� de M�decine, CHRU Pontchaillou, 35033 RENNES, France
Journal: Hepatology (1995)

Remodeling of atrial extracellular matrix (ECM) in atrial fibrillation (AF) involves changes in the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). The contributions of MMPs and TIMPs to the pathogenesis of AF development have not been clearly defined. This study evaluated the in situ activity and expression of gelatinases (MMP-2 and MMP-9) and their relationship with TIMP-1 or TIMP-3 in atria undergoing rapid atrial pacing for the induction of AF (4 weeks' pacing followed by 2 weeks of maintained AF) in pigs. In AF atria, in situ gelatinase activity was mainly localized in the interstitium of atrial myocardium, and was significantly larger than that of sinus rhythm control (i.e., sham control). The significant increase of MMP-9 in its pro-form and mRNA level, but not MMP-2, was shown to be responsible for the increased gelatinase activity in atria with AF. The inhibitory activities of glycosylated TIMP-1 and TIMP-3, but not TIMP-2, in AF tissues were markedly elevated and also localized in the atrial interstitium. TIMP-1 was found to be mostly colocalized with gelatinase activity over the AF tissues, implying the coexistence of gelatinase activity and TIMP-1, but TIMP-3 appeared only partially colocalized and discontinued the gelatinase activity surrounding the cardiomyocytes. TIMP-1 and TIMP-3 may play differential roles in the inhibition of gelatinase activity in vivo. Together with the survey of several MMPs transcripts and the level of transforming growth factor-β1 (TGF-β1), we proposed that the increased activity of gelatinase (i.e., MMP-9), TIMP-1 and TIMP-3 and their interaction may contribute to atrial ECM remodeling of AF.
Summer School in Methods of Immunologic Research and Diagnosis
Journal: JNCI Journal of the National Cancer Institute (1973)

Summer School in Methods of Immunologic Research and Diagnosis Get access JNCI: Journal of the National Cancer Institute, Volume 50, Issue 4, April 1973, Page 1092, https://doi.org/10.1093/jnci/50.4.1092 Published: 01 April 1973
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
Authors: Marc S Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor W Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja C. Weisel, Pia Klöpfer, Dominika Weinelt, Stefan Härtle, Christian Peschel
Journal: Blood (2015)